Puzzling results from HIV vaccine trial

Dec 03, 2007

A potential HIV vaccine that recently failed a clinical trial in the United States may increase some people's chance of catching the virus that causes AIDS.

Top government and drug industry scientists are currently reviewing data from the trial, which unexpectedly found more HIV infections among study participants who had previously been exposed to a common virus called adenovirus, The Washington Times reported Monday.

"We're trying very hard to understand the data more fully and completely," says Nalini Saligram, a spokeswoman for Merck, co-sponsor of the STEP vaccine trial.

Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease, called the trial results "both disappointing and puzzling."

The trial involved 3,000 participants between the ages of 18 and 45 who were at risk of HIV infection based on their behavior.

It ended in September after researchers determined the vaccine failed to decrease either the chance of HIV infection or the amount of virus in people who became infected while taking it.

Copyright 2007 by United Press International

Explore further: Lift U.S. ban on blood donations by gay men, experts say

add to favorites email to friend print save as pdf

Related Stories

Vietnam's taste for cat leaves pets in peril

16 minutes ago

The enduring popularity of "little tiger" as a snack to accompany a beer in Vietnam means that cat owners live in constant fear of animal snatchers, despite an official ban.

Recommended for you

How we got ahead in HIV control

Jul 25, 2014

When AIDS first emerged in the early 1980s, HIV infection was a death sentence. But a global effort has ensured this is no longer the case for a growing number of people.

User comments : 0